Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
FATE
FATE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FATE News
Analysis of Fate Therapeutics' Cash Burn Risks
1d ago
Yahoo Finance
GT Biopharma: Three Drugs Enter Human Trials
2d ago
PRnewswire
GT Biopharma Advances Three Drug Candidates in Clinical Trials
2d ago
Newsfilter
Fate Therapeutics Unveils CAR T-Cell Therapy Data at Major Conferences
May 21 2026
Newsfilter
Cell Therapies Propel Growth in Anti-Aging Market
May 20 2026
Newsfilter
Cell Therapies Propel Growth in Anti-Aging Market
May 20 2026
PRnewswire
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
May 19 2026
Newsfilter
Fate Therapeutics Q1 Earnings Report Analysis
May 13 2026
seekingalpha
FT819 Achieves Significant Clinical Responses in Active SLE Patients Without Conditioning Chemotherapy
May 11 2026
Newsfilter
Fate Therapeutics Selected for FDA CDRP Program to Accelerate FT819 Development
May 05 2026
Newsfilter
Avaí Bio Initiates α-Klotho Cell Production Phase
Mar 27 2026
PRnewswire
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Mar 27 2026
Newsfilter
Avaí Bio Initiates Production of α-Klotho Cell Bank
Mar 18 2026
Globenewswire
Avaí Bio Advances Cell Therapy Production Milestone
Mar 03 2026
PRnewswire
Avaí Bio Advances α-Klotho Cell Production Milestone
Mar 03 2026
Newsfilter
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
Feb 26 2026
seekingalpha
Show More News
